Panacea Pharmaceuticals, Inc.

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Albert Einstein College of Medicine

Rhode Island Hospital

Panacea Pharmaceutical Inc.

Athanor Biosciences, Inc.

Ghanbari, Hossein

Hossein A Ghanbari

Carl R Merril

Zhi-Gang Jiang

Biswajit Biswas

Jack Raymond Wands

Suzanne M De La Monte

Alan H Deutch

Michael Lebowitz

Peter Davies

Michael S Lebowitz

Bijan Almassian

Steven Andrew Fuller

Weiying Pan

Ginger Johnson

Benjamin Wolozin

Suzanne De La Monte

Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides at a surface of the capsid head. Vaccines and methods of forming and using vaccines are described. A vaccine can include an engineered bacteriophage that exhibits an immunogenic exogenous polypeptide at a surface of the bacteriophage. Multivalent bacteriophage and immunogenic bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).

Bacteriophage-based vaccines and engineered bacteriophage

The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-beta-hydroxylase

The present invention provides methods and compositions for treating chemotherapy-induced cognitive impairment. One embodiment of the present invention is directed to a method of treating chemotherapy-induced cognitive impairment by administering to a patient in need at least one thiosemicarbazone compound.

Treatment for chemotherapy-induced cognitive impairment

The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound.

Treatment for chemotherapy-induced peripheral neuropathy

The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.

Radio-imaging and radio-therapy of cancer using antibodies to HAAH

The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-&#x3b2;-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-&#x3b2;-hydroxylase)

The invention is related to the treatment of prion-related diseases such as the transmissible spongiform encephalopathies (TSEs) in mammals by administering chaotropic agents to or inducing a hyperthermia state in the affected mammals.

Methods of treating prion disease in mammals

The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft surgery, Global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage. hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, spinal stroke and spinal cord injury, diseases of cerebral blood vessels: e.g., atherosclerosis, vasculitis, Macular degeneration, myocardial infarction, cardiac ischemia and superaventicular tachyarrhytmia.

Methods of treating ischemic related conditions

The invention features a method for diagnosing and inhibiting growth of a malignant neoplasm in a mammal by contacting a cell or a bodily fluid of the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide. Methods of immunization to generate an HAAH-specific immune response are also within the invention.

Diagnosis and treatment of malignant neoplasms

The invention relates to an antigen associated with Alzheimer's disease and to antibodies specific for said antigen. This invention further relates to methods for diagnosing Alzheimer's disease utilizing assays containing Alzheimer's associated antigen, antibodies specific for said antigen and samples from an individual suspected of having Alzheimer's disease.

The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's

A method for detecting elevated levels of the middle isoform of .alpha.-2 haptoglobin, .alpha.-2FS haptoglobin in bodily fluids of subjects with Alzheimer's disease and schizophrenia as compared with the .alpha.-2FS haptoglobin level in normal subjects. Fibrinogen fragments corresponding to proteins 127 and 128 are also found in elevated levels in such subjects. Elevated levels of specific haptoglobin proteins serve as a diagnostic marker for Alzheimer's disease and Schizophrenia.

Growing community of inventors

Potomac, MD, United States of America

Hossein A Ghanbari